AxoGen (AXGN) investor relations material

Executive summary

• Q2 2026 revenue reached $69.7 million, up 23.1% year-over-year, driven by strong demand in the Breast segment and broad-based growth across all markets.

• Adjusted EBITDA was $8.4 million (12.1% margin), and adjusted net income was $7.3 million; net loss was $1.5 million due to a one-time debt extinguishment loss.

• Cash and investments totaled $113.4 million at quarter-end, with no debt obligations and liquidity strengthened by a $133.3 million equity offering.

• Strategic investment in Trace Biosciences to support nerve-specific imaging technology and innovation initiatives.

• Commercial execution and sales force productivity exceeded expectations, with meaningful increases in active surgeons and accounts.

Financial highlights

• Q2 2026 gross margin was 72.7%, down from 74.2% in Q2 2025, impacted by product mix shift toward higher-cost Breast products.

• Adjusted net income for Q2 was $7.3 million ($0.12 per share), up from $5.7 million in Q2 2025; adjusted EBITDA margin was 12.1%, down from 16.3% in Q2 2025.

• Free cash flow for the first half of 2026 was $4.1 million, a significant improvement from negative $7.2 million in the prior year.

• Operating expenses rose to $52.8 million, mainly from compensation and stock-based expenses tied to revenue growth.

• Cash and investments at June 30, 2026, totaled $113.4 million, up from $41.5 million at year-end 2025.

Outlook and guidance

• Full-year 2026 revenue guidance raised to at least $279 million, reflecting at least 24% growth.

• Gross margin expected to be at least 73% for 2026, with improvement anticipated as product mix broadens.

• Positive free cash flow projected for the full year.

• Guidance does not assume material benefit from future payer coverage decisions beyond those already known.

• Existing cash, investments, and product sales expected to fund operations for at least the next twelve months.